Overall, our work indicates that restoring TET2 function may overcome the negative effects of HDACi administration on DNA demethylation and also provides a rationale to further test combined treatment with a TET2 agonist plus an HDACi against high-risk MDS or AML. The gene discussed is TET2; the disease is myelodysplastic syndrome.